Stanley Druckenmiller and Wall Street Analysts Back Biotech Stock Revolution Medicines
Shares of Revolution Medicines (NASDAQ: RVMD) have surged over 134% this year, driven by positive clinical trial results for its lead drug candidate. Billionaire investor Stanley Druckenmiller's Duquesne Family Office has invested in the company, and major institutional investors like BlackRock and Vanguard also hold significant stakes. Revolution is a clinical-stage biotech firm developing targeted therapies against RAS proteins to replace traditional chemotherapy for aggressive cancers such as pancreatic, lung, and colorectal cancer. Its lead drug, Daraxonrasib, showed promising phase III results in treating metastatic pancreatic cancer patients, with median survival more than doubling compared to standard care. The company is preparing a New Drug Application submission to the FDA after receiving Breakthrough Therapy Designation for its candidate. With $1.9 billion in cash and recent financing of $2.1 billion, Revolution has sufficient capital to advance clinical trials despite ongoing losses due to high R&D costs.
Topics: biotechnology innovation investor activity stock performance